Haby A. Henary

Oncology

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.

Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.

Journal: American journal of hematology

Published: March 20, 2024

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.

Journal: Investigational new drugs

Published: February 12, 2022

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: September 10, 2021

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

Journal: The New England journal of medicine

Published: June 07, 2021

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

Journal: The New England journal of medicine

Published: September 21, 2020

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

Journal: Investigational new drugs

Published: June 28, 2019

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.

Journal: Cancer chemotherapy and pharmacology

Published: April 18, 2019

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Journal: Nature

Published: March 29, 2019

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.

Journal: Blood advances

Published: January 11, 2019

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.

Journal: Cancer chemotherapy and pharmacology

Published: November 27, 2018

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: April 30, 2015

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

Journal: Investigational new drugs

Published: April 14, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026